Immunologic Factors: all 3,292 studies that test it

Page 24 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.

• Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic LymphomaCompletedNCT01732861Phase 1
• Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated VasculitisCompletedNCT01731561Phase 3
• Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT01729806Phase 1
• Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01729104Phase 1
• First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDDTerminatedNCT01728259Phase 1
• Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular LymphomaCompletedNCT01722305Phase 1
• Low-dose Rituximab Regimens in Chinese Adult Patients With Immune ThrombocytopeniaCompletedNCT01719692Not applicable
• Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple SclerosisCompletedNCT01719159Phase 2
• Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.CompletedNCT01718379Phase 2
• Rituximab Trial for Pediatric Nephrotic SyndromeStatus unknownNCT01716442Phase 2/3
• Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT01713738Phase 1/2
• Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent NeuroblastomaActive, not recruitingNCT01711554Phase 1
• A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male SubjectsCompletedNCT01707407Phase 1
• Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLLCompletedNCT01703364Phase 1/2
• Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide MaintenanceCompletedNCT01702831Phase 2
• Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLEWithdrawnNCT01702038Phase 2
• Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's LymphomaCompletedNCT01701232Phase 3
• Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.CompletedNCT01696500Phase 3
• Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaActive, not recruitingNCT01695941Phase 1
• Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed MyelomaStatus unknownNCT01686386Phase 1/2
• Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell LymphomaCompletedNCT01686321Phase 2
• A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate CancerWithdrawnNCT01685489Phase 1
• A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaCompletedNCT01682616Phase 1
• Lenalidomide Plus Chemotherapy for AMLCompletedNCT01681537Phase 1
• Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 ExpressionStatus unknownNCT01681446Phase 3
• Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic SyndromeStatus unknownNCT01673308Phase 2
• A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01671904Phase 1
• Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness?CompletedNCT01653665Phase 1/2
• A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)CompletedNCT01650727Phase 1
• A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular LymphomaCompletedNCT01650701Phase 3
• Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceWithdrawnNCT01647165Phase 2
• Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular LymphomaCompletedNCT01644799Phase 1
• Phase 1b Safety and Efficacy Study of TRU-016TerminatedNCT01644253Phase 1
• Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MFCompletedNCT01644110Phase 1/2
• POEMS Syndrome Treatment With LenalidomideCompletedNCT01639898Phase 2
• A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of ActionCompletedNCT01638715Phase 4
• Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT01629082Phase 1
• IVIG in Acute Ischemic Stroke: A Pilot StudyWithdrawnNCT01628055Phase 1
• Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health OutcomesWithdrawnNCT01625793Not applicable
• Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction ImmunochemotherapyTerminatedNCT01625741Phase 2
• Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell LymphomaCompletedNCT01622439Phase 1/2
• Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple MyelomaTerminatedNCT01617213Phase 2
• Phase I Study of Lenalidomide in Patients With Acute LeukemiaTerminatedNCT01615042Phase 1
• Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + LenalidomideTerminatedNCT01604031Phase 1
• A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT01594229Phase 1
• Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Phase 2
• Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid ArthritisCompletedNCT01593332Phase 4
• NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or SleepinessCompletedNCT01591551Phase 4
• Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple MyelomaCompletedNCT01583283Phase 1
• Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell LymphomaCompletedNCT01582776Phase 1/2
• Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard InductionCompletedNCT01578954Phase 1
• Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple MyelomaCompletedNCT01568294Phase 1
• The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's LymphomasCompletedNCT01567475Phase 1
• Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid MalignanciesCompletedNCT01566656Phase 2
• Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second RelapseCompletedNCT01562990Phase 1/2
• Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCLCompletedNCT01562977Phase 2
• Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT01562405Phase 1
• Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell LymphomaCompletedNCT01560117Phase 2
• A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic LeukemiaCompletedNCT01558167Phase 1/2
• A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line TherapyCompletedNCT01556776Phase 3
• The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).Status unknownNCT01556477Phase 2
• Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous LymphomaCompletedNCT01556035Phase 2
• Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple MyelomaTerminatedNCT01555281Phase 1/2
• Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsStatus unknownNCT01554852Phase 3
• Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)CompletedNCT01553786Phase 2
• Lenalidomide and Dexamethasone in Primary Plasma Cell LeukemiaCompletedNCT01553357Phase 2
• Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic CancerCompletedNCT01547260Phase 1/2
• Lenalidomide as Second-line Treatment for Advanced Hepatocellular CarcinomaCompletedNCT01545804Phase 2
• Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular LymphomaCompletedNCT01542918Phase 1
• Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple MyelomaStatus unknownNCT01541332Phase 1/2
• Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell LymphomaWithdrawnNCT01539174Phase 2
• Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive LymphomasCompletedNCT01538641Phase 2
• Intravenous Immunoglobulins for Post-Polio SyndromeCompletedNCT01537575Phase 3
• Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence TrialTerminatedNCT01534949Phase 1
• Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid ArthritisCompletedNCT01534884Phase 1
• Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple MyelomaCompletedNCT01530594Phase 3
• Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki DiseaseCompletedNCT01524939Phase 4
• Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular LymphomaCompletedNCT01523860Phase 2
• Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell DiseaseCompletedNCT01522547Phase 1
• Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation TreatmentStatus unknownNCT01521689Phase 2
• Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple MyelomaTerminatedNCT01518465Phase 2
• Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk PatientsCompletedNCT01516580Phase 3
• Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab EvaluationCompletedNCT01516567Phase 2
• Pomalidomide and Dexamethasone (PDex) in AL AmyloidosisCompletedNCT01510613Phase 2
• Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney TransplantStatus unknownNCT01502267Phase 2
• Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01497093Phase 1
• Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin LymphomaCompletedNCT01482754Not applicable
• ACVDL Treatment for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01481194Phase 2
• Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaActive, not recruitingNCT01479842Phase 1
• A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male SubjectsCompletedNCT01474330Phase 1
• Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular LymphomaActive, not recruitingNCT01473628Phase 1/2
• Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesCompletedNCT01471067Phase 1
• Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT01470456Phase 2
• A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01464034Phase 1/2
• Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT01461317Phase 2
• Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)CompletedNCT01461018Phase 3
• Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic TransplantationCompletedNCT01460420Phase 1/2
• ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic OsteosarcomaCompletedNCT01459484Phase 2
• Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)CompletedNCT01459211Phase 2
• Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)TerminatedNCT01458548Phase 2

← Immunologic Factors overview